XML 19 R13.htm IDEA: XBRL DOCUMENT
v3.25.3

Marketable Securities | 9 Months Ended
--- | ---
Sep. 30, 2025
Cash and Cash Equivalents [Abstract] |
Marketable Securities | 4. Marketable Securities The following table summarizes the fair value of marketable securities held by the Company and their location in the Company’s condensed consolidated balance sheet (in thousands):
|  | September 30, 2025 |  |  | December 31, 2024 |
Marketable debt securities |  |  |  |  |  |
Included within cash and cash equivalents |  | $ | 18,058 |  |  | $ | 17,432 |
Included within marketable securities |  | $ | — |  |  | $ | 1,992 |
Marketable equity securities |  |  |  |  |  |
Included within marketable securities |  | $ | 23 |  |  | $ | 24 |
Marketable Debt Securities The following tables summarize the available-for-sale debt securities classified within cash and cash equivalents and within marketable securities in the Company’s condensed consolidated balance sheet for the periods presented (in thousands):
|  | September 30, 2025 |
Financial Assets: |  | Amortized Cost |  |  | Unrealized Gains |  |  | Unrealized Losses |  |  | Fair Value |
U.S. Treasury securities |  | $ | 18,057 |  |  | $ | 1 |  |  | $ | — |  |  | $ | 18,058 |
Total |  | $ | 18,057 |  |  | $ | 1 |  |  | $ | — |  |  | $ | 18,058 |
|  | December 31, 2024 |
Financial Assets: |  | Amortized Cost |  |  | Unrealized Gains |  |  | Unrealized Losses |  |  | Fair Value |
U.S. Treasury securities |  | $ | 19,420 |  |  | $ | 4 |  |  | $ | — |  |  | $ | 19,424 |
Total |  | $ | 19,420 |  |  | $ | 4 |  |  | $ | — |  |  | $ | 19,424 |
The Company has not recognized an allowance for credit losses on any securities in an unrealized loss position as of September 30, 2025 or December 31, 2024. The Company believes that any individual unrealized losses represent temporary declines resulting from changes in interest rates, and do not reflect a deterioration of the credit quality of the issuer. The Company does not intend to sell these securities, nor anticipate that these securities will be required to be sold before recovery. As of September 30, 2025, the amortized cost and estimated fair value of the Company’s available-for-sale debt securities by contractual maturity are shown below (in thousands):
Available-for-sale debt securities maturing: |  | Amortized Cost |  |  | Estimated Fair Value |
In one year or less |  | $ | 18,057 |  |  | $ | 18,058 |
Total available-for-sale debt securities |  | $ | 18,057 |  |  | $ | 18,058 |
Marketable Equity Securities Marketable equity securities with readily determinable fair values are reported at fair value with unrealized gains and losses related to mark-to-market adjustments included in income. Lineage’s marketable equity securities are classified as trading securities and for the periods reported have consisted of shares of common stock of OncoCyte Corporation (“OCX”) and of Hadasit Bio-Holdings Ltd. (“HBL”). Lineage has not owned any shares of OCX since June 30, 2024. The value of marketable equity securities is based on the closing price of OCX and HBL common stock on the last trading day of the applicable quarter. The following table represents the realized and unrealized loss on marketable equity securities for the periods presented (in thousands):
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Gain (loss) on marketable equity securities, net |  | $ | 6 |  |  | $ | (6 | ) |  | $ | (1 | ) |  | $ | (21 | )
Less: Loss recognized in earnings on marketable equity securities sold |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 4 |
Unrealized gain (loss) recognized on marketable equity securities held at end of period, net |  | $ | 6 |  |  | $ | (6 | ) |  | $ | (1 | ) |  | $ | (17 | )

X
- References No definition available. + Details
Name: | us-gaap_CashAndCashEquivalentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for investments in certain debt and equity securities. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 940 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/940-320/tableOfContent Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1403 -Paragraph b -Publisher SEC Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/320/tableOfContent Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/942-320/tableOfContent + Details
Name: | us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration